Thermogenesis awarded nih sbir phase i grant to develop key cell processing disposable for quintessence automated manufacturing of gene-engineered autologous cell (geac) therapies

Rancho cordova, calif., sept. 14, 2021 /prnewswire/ -- thermogenesis holdings, inc. (nasdaq: thmo), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the company was awarded a $250,000 phase i small business innovation research (sbir) grant to develop and test the single-use sterile cell processing disposable, that will be used by the fully automated quintessence system.
THMO Ratings Summary
THMO Quant Ranking